论文部分内容阅读
目的观察依达拉奉注射液联合瓜蒌皮注射液治疗急性缺血性脑卒中的临床疗效及安全性。方法将134例急性缺血性脑卒中患者随机分为对照组67例和试验组67例。对照组予以依达拉奉注射液30 mg,qd,静脉滴注;试验组在对照组治疗的基础上,予以瓜蒌皮注射液20 m L,qd,静脉滴注。2组患者均治疗12 d。比较2组患者的临床疗效、神经功能缺损(NIHSS)评分和生活自理能力(BI)评分、C反应蛋白(CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为92.54%(62/67例)和76.12%(51/67例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的NIHSS评分分别为(11.91±2.33)和(13.21±3.35)分,BI评估量表评分分别为(62.32±12.83)和(52.72±16.53)分,CRP分别为(3.92±1.15)和(7.12±1.96)mg·d L-1,IL-6分别为(15.54±4.93)和(19.23±3.84)ng·L-1,TNF-α分别为(26.85±8.75)和(43.73±12.52)ng·m L-1,差异均有统计学意义(均P<0.05)。试验期间,2组患者均未发生药物不良反应。结论依达拉奉注射液联合瓜蒌皮注射液治疗急性缺血性脑卒中的临床疗效确切,其能明显降低患者的神经功能缺损程度,改善血清炎症因子水平,且安全性较高。
Objective To observe the clinical efficacy and safety of edaravone injection combined with melon skin injection in the treatment of acute ischemic stroke. Methods A total of 134 patients with acute ischemic stroke were randomly divided into control group (67 cases) and experimental group (67 cases). The control group was given edaravone injection 30 mg, qd, intravenous infusion; the experimental group in the control group based on the treatment, to be melon skin injection 20 m L, qd, intravenous drip. Two groups of patients were treated for 12 days. The clinical efficacy, NIHSS score and BI score, C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α) levels, and the incidence of adverse drug reactions. Results After treatment, the total effective rate was 92.54% (62/67 cases) and 76.12% (51/67 cases) in the experimental group and the control group, respectively. The difference was statistically significant (P <0.05). After treatment, the NIHSS scores of the test group and the control group were (11.91 ± 2.33) and (13.21 ± 3.35) points respectively, and the BI assessment scale score was (62.32 ± 12.83) and (52.72 ± 16.53) respectively. The CRP were 3.12 ± 1.15 and 7.12 ± 1.96 mg · d L-1, respectively, and IL-6 were (15.54 ± 4.93) and (19.23 ± 3.84) ng · L -1, respectively (43.73 ± 12.52) ng · m L-1, the difference was statistically significant (all P <0.05). During the trial, two groups of patients did not occur adverse drug reactions. Conclusion Edaravone injection combined with melon skin injection in the treatment of acute ischemic stroke clinical curative effect is exact, which can significantly reduce the degree of neurological deficit in patients with improved serum levels of inflammatory cytokines, and higher safety.